Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus
OwnerKathleen D. Danenberginventor
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method of predicting a response to a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus in cancer tissue. This method comprises determining normal tissue genotype for thymidylate synthase of a patient; determining tumor tissue genotype for thymidylate synthase of said patient; comparing the normal tissue genotype with the tumor tissue genotype; determining whether a loss of heterozygosity at the thymidylate synthase locus has occurred in the tumor tissue based on the comparison of the genotypes; and predicting a response to the chemotherapeutic regimen based on the loss of heterozygosity in the tumor sample.
Claims11
1) a method of predicting a response to a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus in cancer tissue, said method comprising:
- (a) determining normal tissue genotype for thymidylate synthase of a patient;
- (b) determining tumor tissue genotype for thymidylate synthase of said patient;
- (c) comparing the normal tissue genotype with the tumor tissue genotype;
- (d) determining whether a loss of heterozygosity at the thymidylate synthase locus has occurred in the tumor tissue based on the comparison of step (c);
- (e) predicting a response to the chemotherapeutic regimen based on the loss of heterozygosity in the tumor sample.
Dependencies are inferred from the claim text.